Sarawak Medichem Pharmaceuticals Inc. - Company Profile

...venture between the state government of Sarawak, Malaysia, and Advanced Life Sciences Inc (Woodridge, Ill.). Sarawak MediChem Pharmaceuticals Inc....

Calanolide A: Sarawak will begin in 3Q02 a U.S. Phase I trial of Calanolide A in 48 volunteers. Sarawak is a 50-50 joint venture between the state government of

Sarawak MediChem Pharmaceuticals Inc. , Lemont, Ill. Product: Calanolide A Business: Infectious diseases Therapeutic category: Viral replication Target: Reverse transcriptase Description: Naturally occurring non-nucleoside reverse transcriptase inhibitor (NNRTI) Indication: Treat HIV infection Endpoint: Safety, pharmacokinetics Status:...

...market or in development include Boehringer Ingelheim Pharmaceuticals Inc. (Ridgefield, Conn.), DuPont Pharma (Wilmington, Del.), Sarawak MediChem Pharmaceuticals Inc....

...additional monotherapy trials prior to conducting Phase II studies in combination with other antiviral drugs. Sarawak MediChem Pharmaceuticals Inc....

(+)-calanolide A: Began Phase Ib study

Sarawak MediChem Pharmaceuticals Inc., Lemont, Ill. Product: (+)-calanolide A Business: Infectious diseases Therapeutic category: Viral replication Target: HIV reverse transcriptase Description: Non-nucleoside reverse transcriptase inhibitor (NNRTI) Indication: Treat HIV infection/AIDS Status: Sarawak, a joint venture...

Sarawak began U.S. Phase Ib testing of (+)-calanolide A

Sarawak MediChem Pharmaceuticals Inc., Lemont, Ill. Product: (+)-calanolide A non-nucleoside reverse transcriptase inhibitor (NNRTI) Indication: Treat HIV infection/AIDS Status: Sarawak began U.S. Phase Ib testing of (+)-calanolide A in 32 treatment-naive HIV-infected patients. The placebo-controlled...

BioCentury | Mar 17, 2003

Clinical News

Calanolide A: Phase I

...venture between the state government of Sarawak, Malaysia, and Advanced Life Sciences Inc (Woodridge, Ill.). Sarawak MediChem Pharmaceuticals Inc....

BioCentury | Jul 15, 2002

Clinical News

Calanolide A: Sarawak will begin in 3Q02 a U.S. Phase I trial of Calanolide A in 48 volunteers. Sarawak is a 50-50 joint venture between the state government of

BioCentury | Jun 25, 2001

Tools & Techniques

Surprise NNRTI finding

...market or in development include Boehringer Ingelheim Pharmaceuticals Inc. (Ridgefield, Conn.), DuPont Pharma (Wilmington, Del.), Sarawak MediChem Pharmaceuticals Inc....

BioCentury | Feb 7, 2000

Clinical News

: Phase Ib

...additional monotherapy trials prior to conducting Phase II studies in combination with other antiviral drugs. Sarawak MediChem Pharmaceuticals Inc....

BioCentury | Jul 19, 1999

Clinical News

(+)-calanolide A: Began Phase Ib study

BioCentury | Oct 5, 1998

Clinical News

Sarawak began U.S. Phase Ib testing of (+)-calanolide A

BioCentury | Feb 9, 1998

Clinical News

Calanolide A naturally occurring non-nucleoside reverse transcriptase inhibitor data

...this summer. Data were presented at the Conference on Retroviruses and Opportunistic Infections in Chicago. Sarawak MediChem Pharmaceuticals Inc....

BioCentury | Jun 23, 1997

Clinical News

(+)-Calanolide A, non-nucleoside blocker of reverse transcriptase: Update

Sarawak MediChem Pharmaceuticals Inc., Lemont, Ill. Product: (+)-Calanolide A, non-nucleoside blocker of reverse transcriptase Indication: Treat AIDS Status: Sarawak last week began Phase Ia testing in 50 patients in a seven-month U.S. trial. A single...

BioCentury | Apr 28, 1997

Company News

MediChem Research Inc., State of Sarawak deal

...The parties formed Sarawak MediChem Pharmaceuticals Inc., a joint venture to advance clinical development of Calanolide A, an HIV...

Calanolide A: Phase I

Calanolide A: Sarawak will begin in 3Q02 a U.S. Phase I trial of Calanolide A in 48 volunteers. Sarawak is a 50-50 joint venture between the state government of

Surprise NNRTI finding

: Phase Ib

(+)-calanolide A: Began Phase Ib study

Sarawak began U.S. Phase Ib testing of (+)-calanolide A

Calanolide A naturally occurring non-nucleoside reverse transcriptase inhibitor data

(+)-Calanolide A, non-nucleoside blocker of reverse transcriptase: Update

MediChem Research Inc., State of Sarawak deal

Calanolide A: Phase I

Calanolide A: Sarawak will begin in 3Q02 a U.S. Phase I trial of Calanolide A in 48 volunteers. Sarawak is a 50-50 joint venture between the state government of

Surprise NNRTI finding

: Phase Ib

(+)-calanolide A: Began Phase Ib study

Sarawak began U.S. Phase Ib testing of (+)-calanolide A

Calanolide A naturally occurring non-nucleoside reverse transcriptase inhibitor data

(+)-Calanolide A, non-nucleoside blocker of reverse transcriptase: Update

MediChem Research Inc., State of Sarawak deal

Products & Solutions

About Biocentury

Contact

Privacy & Legal